Patents by Inventor Elias Zambidis

Elias Zambidis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240384232
    Abstract: The present disclosure relates to methods and compositions for generating both patient-specific and universal donor banked HLA-defined therapeutic progenitors in clinical grade, current good manufacturing practice (cGMP)-compliant conditions from a new class of tankyrase inhibitor-regulated naive human induced pluripotent stem cells (TIRN-hiPSCs).
    Type: Application
    Filed: July 26, 2024
    Publication date: November 21, 2024
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Elias Zambidis, Ludovic Zimmerlin
  • Publication number: 20210275595
    Abstract: Compositions are provided compositions comprising tankyrase/PARP (poly-ADP-ribose polymerase, also known as poly-ADP-ribosyltransferase) inhibitor-regulated naïve human induced pluripotent stem cells (N-hiPSCs) and their use in the treatment of vascular disorders.
    Type: Application
    Filed: February 19, 2021
    Publication date: September 9, 2021
    Inventors: Elias Zambidis, Tea Soon Park
  • Publication number: 20130136721
    Abstract: The invention features a culture system, culture system components and culture methods that are useful for the rapid and reliable generation of differentiated mesodermal cells, including cardiac myocytes, from stem cells, such as human embryonic stem cells and human induced pluripotent stem cells differentiated mesodermal cells, including differentiated cardiac myocytes.
    Type: Application
    Filed: February 9, 2011
    Publication date: May 30, 2013
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Elias Zambidis, Paul Burridge